Non-Small Cell Lung Cancer — A Presentation by Dr Julia Rotow on the Potential Role of PD-1 x VEGF Bispecific Antibodies

Featuring a slide presentation from Dr Julia Rotow, including the following topics:

Rationale and potential clinical role of PD-1/PD-L1 x vascular endothelial growth factor (VEGF) bispecific antibodies in the treatment of non-small cell lung cancer (NSCLC) (0:00)Key findings from the Phase III HARMONi-6 study; ongoing Phase III HARMONi-3 study (5:12)Key findings from the Phase III HARMONi-2 study; ongoing Phase III HARMONi-7 study (9:59)Clinician insights about the potential role of ivonescimab in the front-line setting (12:02)Impetus for investigating ivonescimab in the relapsed/refractory (R/R) EGFR-mutant setting (14:01)Key findings from the Phase III HARMONi-A and HARMONi studies (16:07)Clinician insights about the potential role of ivonescimab in the treatment of R/R EGFR-mutant NSCLC; other novel PD-1/PD-L1 x VEGF bispecific antibodies under investigation (20:30)

CME information and select publications